In situ photoimmunotherapy for melanoma: an ongoing phase I clinical trial
暂无分享,去创建一个
Robert E. Nordquist | Wei R. Chen | Mark F. Naylor | Lisa A. Perry | T. Kent Teague | Wei R. Chen | R. Nordquist | M. Naylor | T. Teague | L. A. Perry
[1] R. Medzhitov,et al. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA , 2006, Nature Immunology.
[2] Rafael F. Martín-García. New insights into imiquimod's mechanisms of action. , 2004, Journal of drugs in dermatology : JDD.
[3] R. Miller,et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. , 1999, Cellular immunology.
[4] G. Schuler,et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. , 2000, Journal of the American Academy of Dermatology.
[5] T. Testerman,et al. Cytokine induction by the immunomodulators imiquimod and S‐27609 , 1995, Journal of leukocyte biology.
[6] K. Bartels,et al. Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: an in vivo efficacy study. , 1996, Cancer letters.
[7] G. Wang,et al. Induction of the , 1996 .
[8] M. Dahl,et al. Imiquimod: an immune response modifier. , 2000, Journal of the American Academy of Dermatology.
[9] Martin F. Mihm,et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Nordquist,et al. In situ photoimmunotherapy: a tumour‐directed treatment for melanoma , 2006, British Journal of Dermatology.
[11] Hong Liu,et al. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. , 2002, Cancer research.
[12] R. Nordquist,et al. Antitumor immunity induced by laser immunotherapy and its adoptive transfer. , 2001, Cancer research.
[13] S. Akira,et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. , 2003, The Journal of clinical investigation.
[14] M. Stanley,et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. , 1999, Antiviral research.
[15] K. Bartels,et al. Chromophore-enhanced in vivo tumor cell destruction using an 808-nm diode laser. , 1995, Cancer letters.
[16] P. Ohashi,et al. Making and breaking tolerance. , 2002, Current opinion in immunology.
[17] M. Jefford,et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. , 2004, Cancer immunity.
[18] R. Nordquist,et al. Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. , 1997, Cancer letters.
[19] S. Akira,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.
[20] V. Cerundolo,et al. Plasmacytoid dendritic cells prime IFN‐γ‐secreting melanoma‐specific CD8 lymphocytes and are found in primary melanoma lesions , 2003, European journal of immunology.
[21] R. Barlow,et al. Topical imiquimod immunotherapy in the management of lentigo maligna , 2004, Clinical and experimental dermatology.
[22] R. Gay,et al. The role of Toll-like receptor signalling in the pathogenesis of arthritis. , 2005, Cellular immunology.
[23] K. Bartels,et al. Chromophore-enhanced laser-tumor tissue photothermal interaction using an 808-nm diode laser. , 1995, Cancer letters.
[24] R. Kuwahara,et al. Treatment of lentigo maligna with topical imiquimod , 2003, The British journal of dermatology.
[25] Yong‐jun Liu,et al. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. , 2005, Annual review of immunology.
[26] M. Tomai,et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. , 1997, Cytokine.
[27] J. Marsden,et al. Imiquimod in the treatment of lentigo maligna , 2006, The British journal of dermatology.
[28] H. Kerl,et al. Topical imiquimod in the treatment of metastatic melanoma to skin. , 2003, Archives of dermatology.
[29] Wei R. Chen,et al. Long‐term tumor resistance induced by laser photo‐immunotherapy , 1999, International journal of cancer.
[30] Hong Liu,et al. Induced antitumor immunity against DMBA‐4 metastatic mammary tumors in rats using laser immunotherapy , 2003, International journal of cancer.
[31] R. Noelle,et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. , 2002, Cellular immunology.
[32] S. Ugurel,et al. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread , 2002, The British journal of dermatology.
[33] B. Bonnekoh,et al. Imiquimod, a Topical Immune Response Modifier, in the Treatment of Cutaneous Metastases of Malignant Melanoma , 2002, Dermatology.